Shubham Pant, MD, MBBS

Shubham Pant, MD, MBBS, is a professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center

Articles

RAS-ON vs RAS-OFF inhibitors in PDAC: Exploring Daraxonrasib

July 1st 2025

Recent breakthroughs in pancreatic cancer treatment focus on novel inhibitors that target the active, GTP-bound “RAS-ON” state—previously considered undruggable—showing promising early trial results with meaningful response rates, reduced circulating tumor DNA, and extended progression-free survival, signaling a potential paradigm shift in managing this historically difficult-to-treat disease.

Treatment After Progression: Navigating Second-Line Options in KRAS-Mutant Pancreatic Cancer

July 1st 2025

Panelists discussed second-line treatment for RAS-mutant pancreatic cancer, emphasizing that sequencing regimens like FOLFIRINOX and gemcitabine-based therapies should be tailored to prior treatment and performance status, while also integrating holistic care—including pain management, nutrition, and early use of molecularly targeted agents—to maximize quality of life and capitalize on critical therapeutic windows.

KRAS in mPDAC: Timing and Value of Testing Amid Limited Treatment

June 24th 2025

Panelists emphasized that early, comprehensive molecular testing at diagnosis—including for RAS mutations—is essential in pancreatic cancer to uncover rare but actionable targets, facilitate timely clinical trial enrollment, and build a foundation for future treatment decisions, even if no immediate therapies are available.

Molecular Profiling in Pancreatic Cancer: RAS Testing and Codon-Specific Interpretation

June 24th 2025

Panelists highlighted how recent breakthroughs in KRAS-specific inhibitors—such as those targeting G12C, G12D, and G12V mutations—are transforming the management of pancreatic cancer, underscoring the importance of precise molecular profiling through tumor-based next-generation sequencing or, when necessary, circulating tumor DNA to guide emerging personalized therapies in this historically challenging disease.

Decoding RAS Mutations: How KRAS Leads in Pancreatic Malignancies

June 17th 2025

Panelists discuss how advancements in molecular oncology are transforming RAS mutations—especially KRAS, but also NRAS and HRAS—from historically “undruggable” targets into promising avenues for personalized therapy in pancreatic and other solid tumors.

Targeting RAS: A Critical Oncogenic Pathway Across Tumor Types

June 17th 2025

Panelists discuss how KRAS mutations, long considered “undruggable” in pancreatic cancer, are now emerging as actionable targets thanks to allele-specific inhibitors, marking a turning point in precision oncology and offering new hope for improving outcomes in a historically treatment-resistant disease.

Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott

May 15th 2025

Pant and Elliott discuss research seeking to extend the benefits of cancer vaccines as cancer management and prevention strategies.

Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

April 2nd 2025

Panelists discuss how recent research presentations and data updates at the latest scientific meeting have advanced the understanding and treatment landscape of biliary tract cancer (BTC).

Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

March 26th 2025

Panelists discuss how significant challenges remain in HER2-positive biliary tract cancer (BTC), including optimizing sequencing of targeted therapies, addressing resistance mechanisms, improving biomarker testing accessibility, and developing strategies for brain metastases.

Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

March 26th 2025

Panelists discuss how treatment selection among HER2-targeted agents for biliary tract cancer (BTC) depends on multiple factors including patient characteristics and prior therapies, while also considering the role of traditional chemotherapy regimens such as FOLFOX in specific clinical scenarios.

Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials

March 19th 2025

Panelists discuss how the MyPathway study and SGNTUC-019 basket trial demonstrated the clinical activity of trastuzumab plus pertuzumab and tucatinib, respectively, in HER2-positive biliary tract cancer (BTC), highlighting key efficacy metrics and safety profiles that inform treatment selection.

New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study

March 19th 2025

Panelists discuss how the HERIZON-BTC-302 study demonstrated zanidatamab's efficacy in HER2-positive biliary tract cancer (BTC) with key end points presented at ASCO GI, while sharing insights on optimal dosing strategies and early real-world experience with this newly approved agent in the second-line setting.

Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

March 12th 2025

Panelists discuss how the DESTINY-PanTumor 02 trial demonstrated significant efficacy of trastuzumab deruxtecan in HER2-amplified biliary tract cancer (BTC), with promising response rates and durability that support its use as a treatment option for these patients.

Understanding HER2 Testing in BTC: Detection and Clinical Approaches

March 12th 2025

Panelists discuss how molecular testing strategies at disease progression are evolving in biliary tract cancer (BTC), with particular focus on HER2-amplification detection methods including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS), while noting that HER2 positivity occurs in approximately 5% to 15% of cases.

Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

March 5th 2025

Panelists discuss how emerging clinical trial data for immunotherapy combinations in first-line advanced biliary tract cancer (BTC) can be effectively translated into real-world treatment decisions, weighing factors such as biomarker status, safety profiles, and treatment sequencing.

Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

March 5th 2025

Panelists discuss how the practice-changing TOPAZ-1 trial established durvalumab plus gemcitabine/cisplatin as a first-line standard for advanced biliary tract cancer (BTC) while exploring key clinical factors that influence the choice between durvalumab and pembrolizumab-based combinations following the KEYNOTE-966 results.

Expert Insights: Challenges With ctDNA Testing in BTC

February 26th 2025

Panelists discuss how circulating tumor DNA (ctDNA) testing in biliary tract cancer (BTC) presents unique technical and interpretative challenges, including considerations around sensitivity, timing of collection, and clinical validation of results.

Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

February 26th 2025

Panelists discuss how clinicians are increasingly utilizing both tissue and liquid biopsies with comprehensive DNA/RNA next-generation sequencing (NGS) for biomarker testing in biliary tract cancer (BTC), while noting variations in testing practices across different treatment centers.

The Importance of Early Biomarker Testing in Managing Advanced BTC

February 19th 2025

Panelists discuss how comprehensive molecular profiling and biomarker testing are critical for guiding targeted therapy decisions in advanced biliary tract cancer (BTC), citing recent real-world data presented at ASCO GI that demonstrated improved outcomes with matched targeted therapies.

Guiding Patients Through Advanced BTC Prognosis and Expectations

February 19th 2025

Panelists discuss how physicians typically communicate survival outcomes and prognosis to patients with newly diagnosed advanced biliary tract cancer (BTC), focusing on setting realistic expectations while maintaining hope.